industryEvidence level E
Evidence pageTakeda Update on Alofisel (darvadstrocel)
Takeda Pharmaceutical Company
Published Dec 13, 2024accessed Nov 11, 2026Updated Nov 11, 2026
Original source
https://www.takeda.com/newsroom/statements/2024/takeda-alofisel-update-2024/
takeda.com
Verification
| Verification | Not yet verified |
| Evidence level | E · Other |
| Independent | Independent of the subject |
| Source | industry |
| Link status | Reachable at last check |
Official claims are statements by the provider; they are not verified by worldwiki unless marked otherwise. Source policy
Cited by (8)
FactAdipose-derived Stem Cell: Phase 3 confirmatory trial result (ADMIRE-CD II) (official claim) = 568 patients; primary endpoint (combined remission at 24 weeks) not met; no statistical difference in secondary endpoints patientsAnswer크론병 치루에 쓰는 지방줄기세포 치료제는 어떤 근거가 있나요?Answer알로피셀(Alofisel)은 왜 유럽에서 허가가 취소됐나요? 국내 제품과 같은 건가요?Answerアロフィセル（ダルバドストロセル）は欧州でなぜ承認が取り下げられたのですか？Answer克罗恩病复杂性肛瘘：Alofisel（达伐妥赛）在欧盟被撤市了，韩国的Cupistem是同一个东西吗？Answerهل توجد منتجات خلايا جذعية دهنية مرخصة رسميا، وفي اي دولة؟Answerهل تفيد حقن الخلايا الجذعية الدهنية في خشونة الركبة او تساقط الشعر او نضارة الوجه؟Answerما مستوى الادلة على استخدام الخلايا الجذعية الدهنية في ناسور داء Crohn، ولماذا سحب ترخيص Alofisel؟